Skip to content
prognosis

Biotech Startup Rome Therapeutics Raises $77 Million in Funding

  • Company focuses on DNA sequences that don’t produce proteins
  • Investor Section 32 sees potential in helping to fight disease
DNA (deoxyribonucleic acid) double helix
DNA (deoxyribonucleic acid) double helix

Photographer: KTSDESIGN/Science Phot Library/Science Photo Library RF

Rome Therapeutics Inc., a biotech company focusing on portions of DNA that have been largely overlooked by researchers, raised $77 million in a financing round. 

The Cambridge, Massachusetts-based company is exploring DNA sequences that repeat themselves hundreds or thousands of times throughout the human body. Unlike most genes, which have only two copies, repetitive sequences are found in vast stretches of the human genome. Collectively, Rome dubs them the “repeatome.”